What’s the Optimal Tumor Model for Your Next Preclinical Immuno-Oncology Study?

Image of Top 5 Tumor Models for Immuno-Oncology Studies - Special Report

Scientists at MI Bioresearch have run close to 1,000 preclinical immuno-oncology studies over the past five years. While new models continue to be developed, our scientists have found the following to be their commonly used “workhorse” models, time-tested and optimized for evaluating a wide range of therapeutic approaches.

The models discussed offer:

  • Diverse histotypes for test agent development
  • Data representing responsiveness to checkpoint inhibitors, costimulatory molecules, and/or focal radiation
  • Corresponding links to posters and other data sources to aid in your decision-making process